For this article in the Daily Telegraph, Hannah Boland spoke with scientific founder Prof. Mauro Giacca, and CEO Richard Francis about Forcefield’s research into identifying proteins which have the potential to arrest the death of critical cells after a heart attack and minimize the risk of heart failure.
About Forcefield Therapeutics Ltd.
Forcefield Therapeutics Ltd (Forcefield Tx) is a pioneer of best-in-class therapeutics to retain heart function via protection of cardiomyocytes. Forcefield Tx was founded by scientists, industry experts and investors with a shared purpose to revolutionise treatment following acute myocardial infarction (MI).
Forcefield’s unique approach can both retain and protect heart cells, minimising the impact of MI and preventing the cascade of events that may lead to subsequent heart failure. Forcefield Tx is led by a proven team with a record of success from discovery to commercialisation and is backed by leading FTSE 250 healthcare company, Syncona.
